Karbe Frank
SEC-identified person · CIK 1276700 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Phathom Pharmaceuticals, Inc. PHAT | Director | filed 2022 - 2026 |
| Cidara Therapeutics, Inc. CDTX | Chief Financial Officer | filed 2025 - 2026 |
| Mountain Crest Acquisition Corp II MCADU | Director · See Remarks | filed 2022 - 2023 |
| Myovant Sciences Ltd. MYOV | Principal Fin'l & Accounting | filed 2016 - 2021 |
| Chinook Therapeutics, INC. KDNY | Director | filed 2019 - 2020 |
| Tekmira Pharmaceuticals Corp TKMR | Director | filed 2014 - 2017 |
| Exelixis, INC. XEL | SVP, CFO | filed 2006 - 2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.